首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANG1 |
| Uniprot No | P03950 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-147aa |
| 氨基酸序列 | DNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP |
| 预测分子量 | 18.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ANG1重组蛋白的经典文献概述：
1. **文献名称**：Angiopoietin-1 protects the adult vasculature against plasma leakage
**作者**：Thurston G 等
**摘要**：该研究通过重组ANG1蛋白在小鼠模型中发现，ANG1能通过激活Tie2受体稳定血管内皮细胞连接，抑制炎症因子诱导的血管渗漏，为治疗血管通透性相关疾病提供依据。
2. **文献名称**：Recombinant angiopoietin-1 restores endotoxin-induced defects in endothelial barrier function
**作者**：Satoshi M 等
**摘要**：体外实验表明，重组ANG1能逆转脂多糖(LPS)诱导的内皮屏障功能障碍，通过调节RhoA信号通路增强细胞间连接完整性，提示其在脓毒症等感染性疾病中的治疗潜力。
3. **文献名称**：Angiopoietin-1 enhances post-ischemic angiogenesis and improves cardiac function
**作者**：Shyu KG 等
**摘要**：在大鼠心肌梗死模型中，注射重组ANG1蛋白显著促进缺血区新生血管形成，减少心肌细胞凋亡，改善心脏收缩功能，为缺血性心脏病治疗提供新策略。
4. **文献名称**：Compartmentalized VEGF/ANG1 signaling directs therapeutic angiogenesis in diabetic retinopathy
**作者**：Joussen AM 等
**摘要**：该研究结合重组ANG1与VEGF的时空表达调控，证明ANG1能抑制糖尿病视网膜病变中病理性血管增生，同时促进正常血管网络重建，为联合治疗提供理论支持。
这些研究从不同角度揭示了重组ANG1蛋白在血管稳定、疾病治疗中的关键作用。
Angiopoietin-1 (ANG1) is a key secretory glycoprotein belonging to the angiopoietin family, primarily involved in vascular development, maturation, and stability. It binds to the Tie2 receptor tyrosine kinase on endothelial cells, triggering signaling pathways that promote vessel remodeling, reduce vascular permeability, and suppress inflammation. Unlike VEGF, which drives early angiogenesis, ANG1 stabilizes nascent vasculature by enhancing endothelial cell survival and cell-matrix adhesion. Its role in maintaining vascular integrity has made it a therapeutic target for conditions involving vascular dysfunction, such as ischemic diseases, diabetic retinopathy, and sepsis.
Recombinant ANG1 protein is engineered using biotechnological methods, often via mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, though bacterial or yeast systems are also employed for cost efficiency. The recombinant form typically retains functional domains, including the coiled-coil and fibrinogen-like domains critical for receptor binding and oligomerization. To enhance stability and solubility, truncated variants (e.g., COMP-ANG1) or fusion tags (e.g., Fc tags) are commonly incorporated.
Preclinical studies highlight its therapeutic potential: in myocardial infarction models, ANG1 improves cardiac function by enhancing collateral circulation; in neurodegenerative diseases, it stabilizes the blood-brain barrier. Additionally, it synergizes with VEGF to promote non-leaky vascular networks in tissue engineering. Challenges include optimizing delivery methods (viral vectors, hydrogels) and balancing pro-angiogenic versus stabilizing effects in cancer contexts. Current research focuses on clinical translation, leveraging ANG1’s dual role in vascular repair and anti-inflammatory signaling to address complex pathologies.
×
